Phases, active trials: Phase 1: 70, Phase 2: 49, Phase 3: 93, Other: 18
Eli Lilly has transformed its portfolio with two breakthrough platforms: GLP-1/GIP receptor agonists for obesity and diabetes (tirzepatide/Mounjaro, retatrutide, orforglipron) and targeted oncology (Verzenio/abemaciclib in breast cancer, Retevmo/selpercatinib for RET-altered cancers, Jaypirca/pirtobrutinib for B-cell malignancies). The obesity franchise is generating an unprecedented volume of Phase 3 trials across cardiometabolic, liver disease, sleep apnea, kidney disease, and other conditions. In immunology, Omvoh (mirikizumab) for IBD and Olumiant (baricitinib) expansions add breadth beyond oncology and metabolic disease.
- Obesity / metabolic disease (GLP-1/GIP)
- Oncology (breast, RET-altered, BTK)
- Immunology / IBD
- Diabetes
- Alzheimer's disease (donanemab)
- Mounjaro / Zepbound (tirzepatide): GLP-1/GIP dual agonist
- Verzenio (abemaciclib): CDK4/6 inhibitor, breast cancer
- Retevmo (selpercatinib): RET inhibitor, NSCLC/thyroid/other
- Jaypirca (pirtobrutinib): non-covalent BTK inhibitor
- Omvoh (mirikizumab): IL-23p19, IBD
- Donanemab: anti-amyloid beta, Alzheimer's
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| A Study of Sofe-M in Participants With Selected Advanced Solid Tumors NCT06400472 | Primary completion moved at least 2 years 3 months later Primary endpoint added | Recruiting |
14 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18… NCT04088396 | Oct 2026 · Estimated | Phase 3 |
16 more on the Completions page. See the calendar →
Monitor the Eli Lilly pipeline daily
Get a daily digest when Eli Lilly registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Obesity | 41 |
| Overweight | 35 |
| Healthy | 16 |
| Alzheimer Disease | 15 |
| Neoplasm Metastasis | 11 |
| Breast Neoplasms | 9 |
| Diabetes Mellitus, Type 2 | 9 |
| Healthy Volunteers | 8 |
Lilly's tirzepatide/GLP-1 platform is the fastest-growing new drug class in history by trial volume. Any company developing obesity, metabolic, or cardiorenal therapeutics needs close visibility into Lilly's expanding label trials. Their oncology pipeline (Verzenio combinations, Retevmo expansions) also generates consistent new Phase 2/3 registrations.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Eli Lilly's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Eli Lilly may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Eli Lilly pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study of LY5625575 in Healthy Participants and in Participants With… NCT07801300 | Recruiting | Recruitment opened | 2026-10-10 |
| A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in… NCT07215559 | Active, Not Recruiting | Enrollment closed, study ongoing | 2026-10-10 |
| A Study of LY4268989 (MORF 057) in Healthy Participants NCT07707375 | Active, Not Recruiting | Enrollment closed, study ongoing | 2026-10-09 |
| A Study of Selpercatinib (LY3527723) in Participants With Rearranged During… NCT07822880 | Not Yet Recruiting | Trial sites expanded: 3 → 10 locations | 2026-10-09 |
| A Study of Eloralintide (LY3841136) in Female Participants With Obesity or… NCT07808060 | Recruiting | Recruitment opened | 2026-10-09 |
Each trial page shows every change DataLookout has recorded for that trial.